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Purpose: The goal of this study was to explore the
tolerability, safety, and treatment response of ﬂexible
doses of once-monthly paliperidone palmitate (PP) in the
subset of nonacute but symptomatic adult patients with
schizophrenia previously unsuccessfully treated with
oral antipsychotic agents in the PALMFlexS (Paliper-
idone Palmitate Flexible Dosing in Schizophrenia) study.
Methods: This was an interventional, single-arm,
international, multicenter, unblinded, 6-month study
performed in patients with schizophrenia. Patients
were categorized according to reasons for switching.
In patients switching because of lack of efﬁcacy or for
other reasons, primary efﬁcacy outcomes were the
proportion achieving treatment response (deﬁned as
Z20% improvement in Positive and Negative Syn-
drome Scale [PANSS] total score from baseline to last-
observation-carried-forward end point) and main-
tained efﬁcacy (deﬁned as noninferiority in the change
in PANSS total score at end point versus baseline
[Schuirmann’s test]), respectively.
Findings: A total of 593 patients (intention-to-treat
population) were enrolled: 63.1% were male; their
mean (SD) age was 38.4 (11.8) years; and 78.6% had
paranoid schizophrenia. The main reasons for tran-
sition to PP were patient’s wish (n ¼ 259 [43.7%]),
lack of efﬁcacy (n ¼ 144 [24.3%]), lack of compliance1372(n ¼ 138 [23.3%]), and lack of tolerability (n ¼ 52
[8.8%]) with the previous oral antipsychotic medica-
tion. The recommended PP initiation regimen (150
milligram equivalents [mg eq] day 1 and 100 mg eq
day 8) was administered in 93.9% of patients. Mean
PANSS total score decreased from 71.5 (14.6) at
baseline to 59.7 (18.1) at end point (mean change,
–11.7 [15.9]; 95% CI, –13.0 to –10.5; P o 0.0001).
Sixty-four percent of patients showed an improvement
ofZ20% in PANSS total score, and the percentage of
patients rated mildly ill or less in Clinical Global
Impression–Severity increased from 31.8% to 63.2%.
Mean personal and social performance total score
(SD) increased (ie, improved) signiﬁcantly for all
patients from baseline to end point (58.1 [13.4] to
66.1 [15.7]; P o 0.0001).
Implications: The PALMFlexS study is a pragmatic
interventional study compared with randomized con-
trolled trials, conducted in a large, more representative
sample of patients with schizophrenia, and designed
speciﬁcally to mimic real-world clinical situations. TheVolume 36 Number 10
A. Schreiner et al.ﬁndings support the results from randomized controlled
studies. They also demonstrate that a clinically relevant
treatment response is possible in patients who are
considered to be clinically stable by their physician,
supporting the use of ﬂexibly dosed PP in such patients.
Clinical trials.gov number: NCT01281527. (Clin Ther.
2014;36:1372–1388) & 2014 The Authors. Published by
Elsevier HS Journals, Inc.
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Schizophrenia is a complex and heterogeneous disor-
der with a range of symptoms that requires long-term
treatment.1 Continuous treatment is particularly
important for patients with schizophrenia because
disruption of long-term treatment increases the risk
of relapse and hospitalization.2
Partial or nonadherence to antipsychotic treatment is
the most important risk factor for relapse,3 and
intermittent therapy has proven inferior to continuous
medication, in both recent-onset and multi-episode pa-
tients.4,5 Although rates of nonadherence within a single
month have been estimated at 40% to 50% after
discharge following a ﬁrst hospital admission,6 several
studies have shown that psychiatrists can often
signiﬁcantly overestimate the extent of adherence to oral
medication.7,8 This oversight is important because, among
other reasons, it may contribute to the underutilization of
long-acting injectable antipsychotic therapy (LAT).6,9 In a
separate study, patients with ﬁrst-episode psychosis who
had responded well in a 2-year open-label trial with
risperidone long-acting injectable therapy10 were followed
up for an additional 3 years. Fifty percent of patients
experienced a relapse within 15 weeks of treatment
discontinuation, and nearly all patients (94%) relapsed
within 2 years.11 These data suggest that treatment
interruption is directly linked to relapse even after long-
term successful treatment, in turn contributing to the
persistence of symptoms and loss of gains in function-
ing and quality of life.12–16 Recent data also suggest
that time in relapse is signiﬁcantly associated with grey
and white matter brain volume loss17 and that
consecutive relapses are highly correlated with
progressive loss in brain volume.18
Relapse is very distressing to patients and caregivers19
and imposes a signiﬁcant ﬁnancial burden on health careOctober 2014systems.20 Furthermore, relapse fuels the progression of
schizophrenia in a variety of ways, including stigma and
loss of self-esteem.21 Thus, the impact of partial or
nonadherence to medication and subsequent relapse
may drive the negative labeling of patients with
schizophrenia and potentially lead to discrimination that
can affect all aspects of a subject’s life, including making
or keeping friends and obtaining a job.22 Nevertheless,
patients often switch or discontinue antipsychotic
therapy, most frequently due to lack of efﬁcacy, adverse
effects, or at their own discretion.23–25
Switching to LAT may improve adherence to treat-
ment in patients with schizophrenia26 due to the
transparency of the medication delivery.27 Partial or
nonadherence in patients with schizophrenia is fre-
quent and multifactorial (eg, due to lack of insight, lack
of social support, negative symptoms, cognitive deﬁcits,
substance abuse). Therefore, greater conﬁ-
dence in the use of LAT could translate into broader
and more effective use of these antipsychotic agents, as
well as improved clinical outcomes.9 LAT has been
shown to signiﬁcantly reduce relapse rates among
patients with schizophrenia compared with those
treated with oral antipsychotic agents,28 although
results of meta-analyses differ depending on the method
used.28–30 For instance, meta-analyses of randomized
controlled trials have not consistently found differ-
ences.28,29 A meta-analysis of mirror-image studies
has shown superiority in favor of LAT versus oral
antipsychotic agents in preventing hospitalization,31
which most likely reﬂects that the comparative
effectiveness of antipsychotic formulations is sensitive
to research design. Indeed, mirror-image studies might
be considered more capable of reﬂecting the relative
impact of LAT compared with oral antipsychotic
agents. However, it should be noted that mirror-
image studies are not free from methodologic bias,
due to the lack of randomization that can limit their
value.32 Data from a study investigating efﬁcacy failure
with paliperidone palmitate (PP) versus haloperidol
decanoate in adult patients with schizophrenia or
schizoaffective disorder, who were assessed as being
at risk of relapse, have shown that the difference in the
rate of efﬁcacy failure was not statistically different for
PP compared with haloperidol decanoate.33
PP is an atypical LAT designed for once-monthly
intramuscular injection34 that has been approved
in the European Union,35 the United States,36 and
450 other countries worldwide, including Australia,1373
Clinical TherapeuticsCanada, Japan, and the People’s Republic of China. In
the European Union, PP is indicated for the main-
tenance treatment of adult patients with schizophre-
nia. Three short-term pivotal studies have reported on
the efﬁcacy and safety of PP. 37–39 These studies used
ﬁxed doses, required an initial washout period before
transition to PP from a previous oral antipsychotic
agent, and were conducted in a well-deﬁned, homoge-
neous, and otherwise healthy group of patients with
schizophrenia. However, a more diverse population of
patients with schizophrenia (eg, with higher rates of
comorbidities, substance abuse, and/or comedications)
is frequently seen in clinical practice. Thus, assessment
of PP in a more representative setting is needed to
obtain information and guidance on dose–response
relationships and strategies for transition or switching
directly from other antipsychotic treatments to PP.
The PALMFlexS (Paliperidone Palmitate Flexible
Dosing in Schizophrenia) study is a pragmatic inter-
ventional study compared with randomized controlled
trials, conducted in a large, more representative
sample of patients with schizophrenia. It was specif-
ically designed to mimic real-world clinical situations
in which the transition to another antipsychotic is
performed in stable, yet previously unsuccessfully
treated, patients. The PALMFlexS study comprised
samples from 3 distinct patient populations: patients
with nonacute schizophrenia switching to PP from
oral antipsychotic agents, nonacute patients switching
to PP from LAT, and acutely ill patients switching to
PP from oral antipsychotics. (The synopsis for the
overall study is available at http://ﬁlehosting.phar
macm.com/DownloadService.ashx?client=CTR_JNJ_
6051&studyid=229&ﬁlename=CR017215_CSR.pdf.)
The primary objective for the group discussed in the
present article was to explore the tolerability, safety,
and treatment response of ﬂexible doses of once-
monthly PP in nonacute but symptomatic adult
patients with schizophrenia previously unsuccessfully
treated with oral antipsychotic agents.
PATIENTS AND METHODS
Study Design
This study was a prospective, interventional, single-
arm, international, multicenter, unblinded, 6-month
study performed in patients with schizophrenia. A total
of 160 sites in 21 countries took part in the study
(Austria, Belgium, Croatia, Denmark, Estonia, France,
Germany, Greece, Hungary, Israel, Italy, Latvia,1374Lithuania, the Netherlands, Portugal, Spain, Sweden,
Switzerland, Turkey, Ukraine, and the United King-
dom). Before trial initiation, the protocol was reviewed
and approved by an independent ethics committee in all
participating countries. The trial was performed in
accordance with the Declaration of Helsinki and was
consistent with the Good Clinical Practice of the Interna-
tional Conference on Harmonisation and applicable
regulatory requirements. Before any trial-related activ-
ities commenced, patients provided their signed consent
to participate in the trial after being informed of the
nature and purpose of the study, participation/termina-
tion conditions, and the risks and beneﬁts of treatment.
The study consisted of a 7-day screening and a
6-month prospective study period. The screening
period included a Z2-day oral tolerability test with
paliperidone extended-release tablets for patients
without source documentation of previous risperidone
or paliperidone exposure. Only patients tolerating the
drug, as judged by the treating physician, were eligible
to enter the 6-month study period, the start of which
was deﬁned as the day of the ﬁrst PP injection.
Patients
Eligible participants were male and female patients
aged Z18 years with a diagnosis of schizophrenia
(Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition [DSM-IV]) who were switched to
PP from an unsuccessful treatment with a previous
oral antipsychotic agent. Patients were required to be
in stable condition but symptomatic (ie, have been on
the same oral antipsychotic given for the treatment of
schizophrenia in an adequate therapeutic dose and
with a change in Clinical Global Impression–Severity
[CGI-S] score r1 in the 4 weeks before enrollment).
Their current treatment was considered to have been
unsuccessful due to 1 or more of the following: lack of
efﬁcacy (baseline Positive and Negative Syndrome
Scale [PANSS] total score Z70 or Z2 items scoring
Z4 in the PANSS positive or negative subscale or Z3
items scoringZ4 in the PANSS general psychopathol-
ogy subscale, as judged by the investigator), lack of
tolerability or safety (the presence of clinically relevant
adverse effects), lack of compliance, or the patient’s
wish. Patients were categorized according to the main
reason for switching, either due to lack of efﬁcacy or
due to other reasons (lack of tolerability, lack of
compliance, or patient’s wish). The following criteria
led to exclusion from study participation: psychiatricVolume 36 Number 10
A. Schreiner et al.diagnosis was due to direct pharmacologic effects of a
substance or a general medical condition; antipsy-
chotic treatment-naive; received clozapine during the
last 3 months before the start of the study; considered
to be at imminent risk of suicide even after clinical
intervention; a history or current symptoms of tardive
dyskinesia or neuroleptic malignant syndrome; preg-
nant or breastfeeding; or known allergies, hypersensi-
tivity, or intolerance to risperidone or paliperidone or
its excipients. Patients with current substance use or
abuse, with the exception of intravenous drug use,
were eligible for enrollment. There were no exclusions
based on body mass index (BMI).
Treatment
PP was initiated at 150 milligram equivalents (mg eq)
on day 1 and 100 mg eq on day 8 (2 days) intra-
muscularly, both given in the deltoid muscle. Deltoid
injections were to be alternated between the 2 deltoid
muscles. At initiation of PP, patients were tapered off
their previous oral antipsychotic, preferably within a
maximum of 4 weeks, at the discretion of the treating
physician. Subsequently, PP was administered once
monthly in either the deltoid or gluteal muscle on days
38, 68, 98, 128, and 158 (7 days) using ﬂexible
maintenance dosages within the range of 50 to 150 mg
eq. Other than PP, no long-acting antipsychotic was
allowed throughout the entire study. Psychotropic med-
ications or other antipsychotic drugs given before study
start for reasons other than the disease itself (eg, sleep
induction or sedation) could be continued during the
study at a stable dose. In case of worsening of psychotic
symptoms between visits that required immediate inter-
vention, oral antipsychotic medication (preferably pal-
iperidone extended-release) could be given within the
approved dose range. Benzodiazepines that were newly
initiated during the study were allowed for rescue
medication, preferably not for a period exceeding 10
consecutive days. Benztropine mesylate or biperiden up
to 4 mg/d (or its equivalent if benztropine mesylate was
not locally available) or trihexyphenidyl up to 10 mg/d
could be used for the treatment of extrapyramidal motor
symptoms (EPMS). The need for benzodiazepines and
anticholinergic medication had to be re-evaluated on an
ongoing basis.
Efficacy Assessments
The primary efﬁcacy outcome for nonacute patients
switched from previous oral antipsychotic medicationOctober 2014due to lack of efﬁcacy was the percentage of patients
achieving treatment response, deﬁned as Z20% im-
provement in PANSS total score from baseline (day 1)
to last-observation-carried-forward (LOCF) end point
(at 6 months or early discontinuation). Improved
efﬁcacy of Z20% was speciﬁed as the primary end
point in this group of patients, as they were considered
stable by their treating physician for at least 1 month
before enrollment while being prescribed an adequate
dose of a highly potent antipsychotic drug; therefore,
their improvement would not be expected to be
comparable to what generally would be observed
in acutely ill patients in whom Z30% or Z50%
improvements are considered more adequate. The
PANSS was completed by trained and qualiﬁed raters
who were aware that the patient was receiving PP in
the setting of a clinical study. All PANSS raters
completed a study-speciﬁc rater training and qualiﬁ-
cation program. Each rater was required to meet the
standard of 80% concordance with the acceptable
scores or score ranges for the videotaped interview.
For patients switching for other reasons, the primary
efﬁcacy outcome was maintained efﬁcacy from base-
line to end point, deﬁned as noninferiority in the
change in PANSS total score at end point versus
baseline, as measured by using Schuirmann’s test.
Actual values and changes from baseline (day 1) in
PANSS total score and CGI-S scale score (on a range
from 1 [not ill] to 7 [extremely ill]) were analyzed.
Clinical Global Impression–Change scores were also
recorded, and relative frequency distributions were
calculated for CGI-S and CGI-Change scores.
Secondary outcomes encompassed actual values
and changes from baseline in PANSS total score,
PANSS sub scale scores, and PANSS Marder factor
scores40 (positive symptoms, negative symptoms, dis-
organized thoughts, uncontrolled hostility/excitement
and anxiety/depression), Personal and Social
Performance (PSP) total score, PSP domain scores41
(socially useful activities including work and studies,
personal and social relationships, self-care, disturbing
and aggressive behaviors, each rated on a 6-point
scale (ranging from 0 [absent] to 5 [very severe]), by
converting to a score ranging from 1–100). Also
evaluated were actual values and changes from
baseline in subjective well-being (assessed by using
the Subjective Well-being under Neuroleptics Scale
according to a 6-point Likert scale ranging from 1
[not at all] to 6 [very much] with 5 subscores [mental1375
Clinical Therapeuticsfunctioning, social integration, emotional regulation,
physical functioning, and self-control] and a total
score),42 treatment satisfaction (assessed in patients
by using the 14-item Treatment Satisfaction Ques-
tionnaire for Medication scale and physician treat-
ment satisfaction by using a 7-point categorical scale),
sleep and daytime drowsiness (evaluated by using
an 11-point categorical rating scale),43 and caregiver
burden (evaluated by using the Involvement Eval-
uation Questionnaire)44 in patients with a care-
giver and depending on the availability of the scale
in the local language. Assessment of abilities/
capabilities deemed critical for social reintegration
and functioning was conducted by using the Mini–
International Classiﬁcation of Functionality, Disability
and Health Rating for Activity and Participation
Disorders in Psychological Illnesses (Mini-ICF-APP)
scale45–47 and summarized descriptively at each as-
sessment point including LOCF end point (Mini-ICF-
APP scale items may be used to evaluate patient’s
capabilities in clinical routine). Each dimension was
rated on a Likert scale ranging from 0 (no disability)
to 4 (total disability).
Tolerability and Safety
EPMS were assessed by using the Extrapyramidal
Symptom Rating Scale.48 Weight was recorded at
each assessment point (including LOCF end point),
and BMI was calculated. All treatment-emergent
adverse events (TEAEs), deﬁned as AEs that were
new in onset or were aggravated in severity after
initiation of PP, were documented and coded by
using the Medical Dictionary for Regulatory Activ-
ities (version 13.0).
Data Analysis
For patients switching due to lack of efﬁcacy, the
proportion with at least 20% improvement in PANSS
total score was expected to be 30%. Using the large
sample normal approximation, it was estimated that
at least 81 patients were required to reach a 95% CI
for a single proportion that maximally extends 10%
from the observed proportion. For patients switching
for other reasons, a mean difference of 5 points
between baseline and end point on the PANSS total
score was considered to be a minimum clinically
relevant difference for maintained efﬁcacy. Using
Schuirmann’s test, it was estimated that 124 patients
were required to test for noninferiority, assuming1376a SD of 17 points, a power of 90%, and a 1-sided
signiﬁcance level of 0.025. A sample size of 600
patients was chosen to explore additional subgroups
such as the different oral antipsychotic from which
patients were switched and recently diagnosed versus
more chronic patients; this sample size would also
account for patients with no analyzable data.
The intention-to-treat (ITT) population comprised
all patients who received PP at least once. The efﬁcacy
analysis population included all ITT patients with at
least 1 postbaseline assessment on any efﬁcacy param-
eter. Treatment response analyses were performed on
the efﬁcacy ITT population.
End point analysis using the LOCF method was
performed in addition to observed case analysis.
Actual values and changes from baseline were sum-
marized descriptively at each assessment time point
and at the patient’s last evaluation (LOCF end point),
and categorical variables were summarized with fre-
quency and percentage. Safety and tolerability were
evaluated throughout the study on the safety ITT
population, which comprised all ITT patients who had
at least 1 postbaseline observation on any safety
parameter. On the level of all reported TEAEs,
frequency distributions that were calculated included
severity of the events (ie, mild, moderate, severe) and
causal relationship to treatment (ie, not related,
doubtful, possible, probable, very likely).
Quantitative differences between subgroups ac-
cording to reason for switching were also tested by
means of the Wilcoxon 2-sample test.
RESULTS
Demographic Characteristics and Patient
Disposition
Overall, the ITT population consisted of 593 non-
acute but symptomatic patients switched from oral
antipsychotic agents who received at least 1 dose of PP
during the study. Patient disposition is described in
Figure 1. The main reasons for transition to PP were
patient’s wish (n ¼ 259 [43.7%]), lack of efﬁcacy (n ¼
144 [24.3%]), lack of compliance (n ¼ 138 [23.3%]),
and lack of tolerability (n ¼ 52 [8.8%]) with the
previous oral antipsychotic medication. A total of 442
(74.5%) patients completed the study. The proportion
of patients completing the study, as well as the main
reasons for withdrawal, was similar across subgroups
by reason for switching: 72.9% (n ¼ 105) for patients
switching due to lack of efﬁcacy and 75.1% (n ¼ 337)Volume 36 Number 10
ITT population*
N = 593
Study completers: n = 442 (74.5%)
Most common (>2%) reasons for early
discontinuation:
Withdrawal of consent: n = 60 (10.1%)•
•
•
•
Adverse event: n = 36 (6.1%)
Loss to follow-up: n = 19 (3.2%)
Lack of efficacy: n = 15 (2.5%)
Efficacy ITT population: 589
Safety ITT population: 593
Figure 1. Patient disposition. *Patients who
received at least one dose of study
drug. ITT ¼ intention-to-treat.
A. Schreiner et al.for patients switching for other reasons. The main
reasons for early study discontinuation for all patients
were withdrawal of consent (n ¼ 60 [10.1%]), an AE
(n ¼ 36 [6.1%]), loss to follow-up (n ¼ 19 [3.2%]),
and lack of efﬁcacy (n ¼ 15 [2.5%]).
The majority of patients were male (63.1%) and
had a diagnosis of paranoid schizophrenia (78.6%)
(Table I). Most (n ¼ 360 [60.7%]) patients had been
previously hospitalized at least twice. At baseline,
patients had a mean (SD) PANSS total score of 71.5
(14.6) and a mean baseline CGI-S score of 3.9 (0.9).
Overall, 363 patients (61.2%) had at least 1 comor-
bidity at baseline, and 382 patients (64.4%) were
treated with at least 1 concomitant medication before
the study. The most frequently reported previous
antipsychotic medications are presented in Table II.
At baseline, 47 patients (9.0%) were reported to have
some kind of substance abuse (with or without
impairment).
After the day 1/day 8 initiation regimen, the PP
mean modal maintenance dose for all patients was
101.4 (33.4) mg eq (Table I). Nearly all (n ¼ 557
[93.9%]) patients received PP according to the
recommended regimen on day 1 (150 mg eq) and
day 8 (100 mg eq). The mean modal maintenance
dose was higher for patients switching for lack of
efﬁcacy than those switching for other reasons; for
example, a higher proportion of patients switching for
lack of efﬁcacy received 150 mg eq as the third dose.
Approximately one half of patients (n ¼ 287 [48.4%])
had 1 dosage adjustment during the study; 14.5%
(n ¼ 86) had 2 dose adjustments and 9.9% (n ¼ 59)
42 dose adjustments (which included any dose changes
made after administration of the third dose). The most
common reason for maintenance dose adjustment wasOctober 2014insufﬁcient efﬁcacy (n ¼ 198 [33.4%]). Most dose
adjustments were dose reductions (57.8%) rather than
dose increases (42.2%).
Efficacy Outcomes
In total, 61.5% of patients who switched for lack
of efﬁcacy showed an improvement ofZ20% in mean
PANSS total score at LOCF end point (Table III).
Efﬁcacy was maintained (ie, change in PANSS total
score at end point vs baseline was not inferior as
measured by using Schuirmann’s test, P o 0.0001) in
patients who switched for reasons other than lack of
efﬁcacy. In this group, 64.8% of patients had an
improvement of Z20% in PANSS total score at
LOCF end point.
The baseline mean PANSS total score was 11.7
points higher for patients who switched due to
lack of efﬁcacy compared with those who switched
for other reasons (Table IV). Mean PANSS total
score signiﬁcantly improved (baseline to LOCF end
point, P o 0.0001) for the total ITT efﬁcacy
population, including those who switched due to
lack of efﬁcacy and those who switched for other
reasons (Figure 2).
The PANSS subscale and factor scores at baseline
were statistically signiﬁcantly higher (P o 0.0001) on
Wilcoxon 2-sample testing in patients switched for
efﬁcacy reasons compared with patients switched for
other reasons. The change in mean PANSS total score
was similar for patients switching due to lack of
efﬁcacy or for other reasons (mean [SD] change of –
12.1 [15.1] and –11.6 [16.2], P ¼ 0.8252 [baseline to
LOCF end point], respectively). There was a statisti-
cally signiﬁcant (P o 0.0001 [baseline to LOCF end
point]) decrease (ie, improvement) for all patients in
all PANSS subscale (Table IV) and PANSS Marder
factor scores (see Supplemental Table in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.
08.014).
The CGI-S scale score for all patients improved
signiﬁcantly (mean [SD] decrease, –0.6 [1.0]; P o
0.0001 [baseline and LOCF end point]) (Table IV).
The change in mean CGI-S scale score was similar for
patients switching due to lack of efﬁcacy or for other
reasons (mean [SD] changes of –0.6 [0.9] and –0.6
[1.1], P ¼ 0.7621 [baseline to LOCF end point;
Wilcoxon 2-sample test]). The proportion of all
patients rated mildly or less ill based on the CGI-S
scale score increased from 31.8% (n ¼ 186) at1377
Table I. Patient baseline demographic characteristics and dosing information (intention-to-treat population).
Characteristic
Total
(N ¼ 593)
Switched for Lack of
Efﬁcacy (n ¼ 144)
Switched for Other
Reasons (n ¼ 449)
Age, y* 38.4 (11.8) 39.8 (12.2) 38.0 (11.7)
Sex, %
Male 63.1 61.1 63.7
Female 36.9 38.9 36.3
Schizophrenia diagnosis, no. (%)
Paranoid 466 (78.6) 114 (79.2) 352 (78.4)
Disorganized 43 (7.3) 7 (4.9) 36 (8.0)
Catatonic 5 (0.8) 1 (0.7) 4 (0.9)
Undifferentiated 54 (9.1) 15 (10.4) 39 (8.7)
Residual 25 (4.2) 7 (4.9) 18 (4.0)
Years since ﬁrst psychotic symptoms* 12.1 (9.6) 12.8 (10.0) 11.9 (9.4)
Weight, kg* 81.0 (17.7) 80.7 (17.1) 81.1 (17.9)
Body mass index, kg/m2* 27.6 (5.9) 27.8 (6.2) 27.6 (5.8)
Patients with Z1 comorbidity, no. (%)† 363 (61.2) 86 (59.7) 277 (61.7)
Body systems for which patients (Z5%) report Z1
comorbidity
Psychiatric disorders 131 (22.1)
Metabolism and nutrition disorders 91 (15.3)
Nervous system disorders 83 (14.0)
Vascular disorders 52 (8.8)
Gastrointestinal disorders 51 (8.6)
Respiratory, thoracic, and mediastinal disorders 44 (7.4)
Infections and infestations 36 (6.1)
Musculoskeletal and connective tissue disorders 35 (5.9)
No. (%) of patients with previous hospitalizations
None 113 (19.1) 21 (14.6) 92 (20.5)
1 120 (20.2) 30 (20.8) 90 (20.0)
Z2 360 (60.7) 93 (64.6) 267 (59.5)
PP dosing
No. (%) of patients receiving PP initiation regimen
at day 1 and day 8 according to protocol‡
557 (93.9) 137 (95.1) 420 (93.5)
Modal PP maintenance dose, mg eq*,§ 101.4 (33.4) 106.3 (33.7) 99.8 (33.2)
Last PP maintenance dose received (n¼ 541), no. (%)
50 mg eq 52 (9.6) 8 (6.1) 44 (10.7)
75 mg eq 168 (31.1) 33 (25.2) 135 (32.9)
100 mg eq 172 (31.8) 44 (33.6) 128 (31.2)
150 mg eq 149 (27.5) 46 (35.1) 103 (25.1)
Relevant comedications
No. (%) of patients using benzodiazepines
At baseline 138 (23.3) 35 (24.3) 103 (22.9)
Newly initiated during study 125 (21.1) 24 (16.7) 101 (22.5)
At LOCF end point 123 (20.7) 27 (18.8) 96 (21.4)
(continued)
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Table I. (continued).
Characteristic
Total
(N ¼ 593)
Switched for Lack of
Efﬁcacy (n ¼ 144)
Switched for Other
Reasons (n ¼ 449)
At 6 months for completers¶ 85 (19.2) 23 (21.9) 62 (18.4)
No. (%) of patients using anticholinergics
At baseline 67 (11.3) 22 (15.3) 45 (10.0)
Newly initiated during study 48 (8.1) 14 (9.7) 34 (7.6)
At LOCF end point 46 (7.8) 16 (11.1) 30 (6.7)
At 6 months for completers¶ 31 (7.0) 11 (10.5) 20 (5.9)
LOCF ¼ last-observation-carried-forward; mg eq ¼ milligram equivalents; PANSS ¼ Positive and Negative Syndrome Scale;
PP ¼ paliperidone palmitate.
*Mean (SD).
†Individual patients can be labeled for 41 comorbidity.
‡The recommended initiation regimen was PP 150 mg eq on day 1 and 100 mg eq on day 8 given in the deltoid muscle.
§Excluding the initiation regimen (day 1/day 8).
¶Total, n ¼ 442; switched for lack of efﬁcacy, n ¼ 105; switched for other reasons, n ¼ 337.
A. Schreiner et al.baseline to 63.2% (n ¼ 370) at LOCF end point
(Figure 3).
Measures of patients’ Subjective Well-being under
the Neuroleptics Scale score, and patient’s satisfactionTable II. Ten most frequent previous oral antipsycho
palmitate at baseline.*
Antipsychotic
Reported Daily Dose (mg)
No. of Patients
Mean (S
Daily Dose
Risperidone 206 4.3 (2.
Paliperidone ER 116 7.6 (2.
Olanzapine 101 15.4 (8.
Aripiprazole 65 21.8 (11
Quetiapine 39 438.5 (27
Haloperidol 37 10.6 (8.
Amisulpride 29 503.5 (28
Quetiapine fumarate 26 450.2 (28
Sertindole 7 9.1 (5.
Ziprasidone 5 128.0 (85
ER ¼ extended-release.
*For 591 patients, the switch medication and the dose were kno
†The duration of use of switch medication was not available fo
October 2014with medication (Treatment Satisfaction Question-
naire for Medication global satisfaction score), sleep
quality, and daytime drowsiness also showed clinically
relevant and statistically signiﬁcant improvementstic medications before switching to paliperidone
Reported Duration† (d)
D)
(mg) No. of Patients
Mean (SD) Duration
of Prior Use (d)
3) 33 257.6 (468.4)
8) 26 118.4 (161.4)
1) 30 191.9 (281.7)
.4) 21 262.9 (318.5)
1.8) 10 222.0 (257.7)
3) 13 456.5 (517.1)
7.2) 7 420.6 (584.5)
5.3) 5 371.0 (466.4)
0) 1 69.0 (-)
.6) 2 116.5 (112.4)
wn.
r all patients.
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Table III. Proportion of patients with improvement in Positive and Negative Syndrome Scale total score (%) at
last-observation-carried-forward end point.
Improvement
Patient Switched For:
Total Population (%)
(n ¼ 589)
Lack of Efﬁcacy (%)
(n ¼ 143)
Other Reasons (%)
(n ¼ 446)
Z20% improvement (95% CI) 64.0 (60–68) 61.5 (53–69) 64.8 (60–69)
Z30% improvement (95% CI) 51.4 (47–55) 39.9 (32–48) 55.2 (51–60)
Z50% improvement (95% CI) 30.4 (27–34) 16.8 (12–24) 34.8 (30–39)
Clinical Therapeutics(P o 0.0001 for all values [baseline to LOCF end
point]) (Table IV). There were no signiﬁcant differ-
ences for these parameters between subgroups based
on reason for switching. There was also a statistically
signiﬁcant improvement in physicians’ satisfaction
scores for all aspects of treatment (efﬁcacy, safety,
mode of administration, and overall satisfaction; all,
P o 0.0001 [baseline to LOCF end point]).
Functioning Outcomes
The mean (SD) PSP total score increased (ie,
improved) signiﬁcantly for all patients (58.1 [13.4]
to 66.1 [15.7], P o 0.0001 [baseline to LOCF end
point]). Baseline functioning in PSP was statistically
signiﬁcantly higher in patients switched for other
reasons (59.0 [13.6]) compared with patients switched
for efﬁcacy reasons (55.3 [12.3]; Po 0.01 [baseline to
LOCF end point], Wilcoxon 2-sample testing), as was
the change in PSP total score (8.8 [14.4] vs 5.5 [12.3],
respectively; P o 0.05 [baseline to LOCF end point]).
Improvement in patient functioning was also reﬂected
in the distribution of PSP total scores (Figure 4A) and
in the distribution in categories of functional
impairment for selected PSP domains (Figure 4B).
Illness-related disabilities in activity and participa-
tion also improved signiﬁcantly (19.8 [7.9] to 15.9
[8.8]; P o 0.0001 [baseline to LOCF end point])
according to Mini-ICF-APP total scores. Statistically
signiﬁcant improvements were observed across all
domains of activity and participation as measured
by using the Mini-ICF-APP (all P values o 0.0001)
(Figure 5).
Tolerability and Safety
During the study, 59.7% (n ¼ 354) of patients
experienced at least 1 TEAE. Most TEAEs (93.1%)1380were rated as mild or moderate in intensity. TEAEs
occurring in Z5% of patients were injection site pain
(n ¼ 73 [12.3%]), insomnia (n ¼ 51 [8.6%]), anxiety
(n ¼ 40 [6.7%]), psychotic disorder (n ¼ 36 [6.1%]),
and headache (n ¼ 33 [5.6%]) (Table V). The majority
(75.8%) of TEAEs resulted in no change in dosage.
Eighteen (3.0%) patients reported at least 1 poten-
tially prolactin-related TEAE, 4 (0.7%) patients re-
ported hyperprolactinemia, and 7 (1.2%) patients
reported a potentially prolactin-related TEAE as well
as hyperprolactinemia. There were no obligatory
protocol-based laboratory tests during this pragmatic
study. The mean Extrapyramidal Symptom Rating Scale
total score at baseline was 2.8 in the whole group,
indicating low levels of EPMS. Nevertheless, there was a
statistically signiﬁcant reduction in Extrapyramidal
Symptom Rating Scale total score (2.8 [5.0] to 1.6
[3.8], P o 0.0001 [baseline to LOCF end point]). The
proportion of patients who received anticholinergic
agents had a reduction from baseline to end point in
both subgroups (Table I). There was a mean (SD)
increase of 0.4 (1.8) kg/m2 (95% CI, 0.3–0.6) in BMI
and a mean weight change between baseline and end
point of 1.2 (5.0) kg (95% CI, 0.7–1.6) in the whole
group. In total, 81 (15.4%) patients had a Z7%
increase in weight from baseline to LOCF end point.
Overall, 42 (7.1%) patients reported Z1 AE that
led to early termination of the study. Two deaths
(completed suicides) occurred during the study; both
were male subjects (26 and 31 years old). These
deaths were considered by the investigator as not
related and doubtfully related, respectively, to the
study drug.
The proportion of patients with substance abuse,
which was low at baseline (9.0%), decreased to 6.9%
at LOCF end point.Volume 36 Number 10
Table IV. Secondary outcomes.*
Outcome Baseline (Mean [SD]) LOCF End Point (Mean [SD])
Mean (SD) Change
From Baseline to LOCF End Point 95% CI P†
Mean PANSS total score
All patients (n ¼ 589) 71.5 (14.6) 59.7 (18.1) –11.7 (15.9) –13.0 to –10.5 o0.0001
Patients switched for lack of efﬁcacy (n ¼ 143) 80.3 (11.3) 68.2 (17.0) –12.1 (15.1) –14.6 to –9.6 o0.0001
Patients switched for other reasons (n ¼ 446) 68.6 (14.4) 57.0 (17.6) –11.6 (16.2) –13.1 to –10.1 o0.0001
Mean PANSS Positive Subscale
All patients (n ¼ 589) 15.5 (4.9) 12.7 (5.1) –2.8 (4.9) –3.2 to –2.4 o0.0001
Patients switched for lack of efﬁcacy (n ¼ 143) 17.1 (4.2) 14.5 (5.4) –2.6 (5.0) –3.6 to –1.8 o0.0001
Patients switched for other reasons (n ¼ 446) 15.0 (5.0) 12.1 (4.9) –2.9 (4.9) –3.3 to –2.4 o0.0001
Mean PANSS Negative Subscale
All patients(n ¼ 589) 20.2 (5.4) 16.7 (5.9) –3.5 (5.4) –3.9 to –3.0 o0.0001
Patients switched for lack of efﬁcacy (n ¼ 143) 23.1 (4.9) 19.5 (5.4) –3.6 (4.9) –4.4 to –2.8 o0.0001
Patients switched for other reasons (n ¼ 446) 19.3 (5.2) 15.8 (5.7) –3.5 (5.5) –4.0 to –2.9 o0.0001
Mean PANSS General
Psychopathology Subscale
All patients (n ¼ 589) 35.8 (8.0) 30.3 (9.2) –5.5 (8.4) –7.3 to –4.6 o0.0001
Patients switched for lack of efﬁcacy (n ¼ 143) 40.1 (6.7) 34.1 (8.8) –6.0 (8.1) –6.1 to –4.5 o0.0001
Patients switched for other reasons (n ¼ 446) 34.4 (7.9) 29.1 (9.0) –5.3 (8.5) –6.1 to –4.8 o0.0001
CGI-S Score
All patients (n ¼ 585) 3.9 (0.9) 3.3 (1.1) –0.6 (1.0) –0.7 to –0.5 o0.0001
SWN-S total Score
All patients (n ¼ 521) 80.1 (17.2) 85.5 (17.3) 5.4 (15.7) 4.0 to 6.7 o0.0001
TSQM global satisfaction score
All patients (n ¼ 494) 55.9 (21.5) 65.0 (25.1) 9.1 (29.0) 6.6 to 11.7 o0.0001
Quality of sleep score‡
All patients (n ¼ 582) 6.8 (2.6) 7.3 (2.4) 0.5 (2.8) 0.3 to 0.7 o0.0001
Drowsiness score§
All patients (n ¼ 582) 3.9 (2.9) 3.1 (2.8) –0.9 (3.4) –1.1 to –0.6 o0.0001
CGI-S ¼ Clinical Global Impression–Severity; LOCF ¼ last-observation-carried-forward; PANSS ¼ Positive and Negative Syndrome Scale; SWN-S ¼ Subjective Well-
being under Neuroleptics Scale; TSQM ¼ Treatment Satisfaction Questionnaire for Medication.
*Only patients with a valid baseline measurement and at least 1 valid follow-up assessment were included.
†Within-group difference was tested by using the Wilcoxon signed-rank test.
‡A higher score indicates improvements in the quality of sleep.
§A lower score indicates improvements in the level of drowsiness.
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Clinical TherapeuticsDISCUSSION
Data from the present study support results provided
by previous ﬁxed-dose, randomized controlled clinical
trials in which the efﬁcacy of PP in the treatment of
schizophrenia has been demonstrated. Furthermore,
our ﬁndings expand on results from studies in stabi-
lized patients with schizophrenia, which demonstrated
greater improvements in clinical symptoms and func-
tioning when switched to an LAT.49–51 It should be
considered that injectable therapy may indirectly
inﬂuence the observed efﬁcacy beneﬁts of treatment
with PP due to the increased interaction with health
care professionals that may occur when administering
LAT. However, the design of the present study does
provide clinical experience of longer-term treatment
with PP, drawing on the clinical judgment of efﬁcacy
and tolerability of the investigating physicians to
access the most appropriate dose of PP that a patient
receives.
Pragmatic studies are considered relevant because
they add to the different levels of evidence available
regarding treatments,28,31 and by examining the effect
size of the change, rather than the question of whether1382there has been improvement, helps to put the data into
perspective. In this study, nonacute but symptomatic
patients with schizophrenia switched to ﬂexibly dosedVolume 36 Number 10
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Figure 5. Mean Mini International Classification
of Functionality, Disability and Health
(ICF) Rating for Activity and Participa-
tion Disorders in Psychological Illnesses
(Mini-ICF-APP) domain scores at base-
line and last-observation-carried-for-
ward (LOCF) end point. Change from
baseline to month LOCF P o 0.0001
for all domains.
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October 2014PP from their previous unsuccessful oral antipsychotic
medication reported signiﬁcant and clinically relevant
improvements in clinical symptoms, disease severity,
psychosocial functioning, and relevant ability domains
of activation and participation comparable to the
effects seen in randomized controlled clinical trials.
However, contrary to most randomized controlled
clinical trials, the pragmatic and ﬂexible dose design
of this study allowed treating physicians to adjust and
optimize antipsychotic treatment with PP based on
patients’ individual needs, which more closely resem-
bles clinical practice. A further advantage is that
patient continuation with treatment is potentiallyTable V. Treatment-emergent adverse events
experienced byZ5% of patients (safety,
intention-to-treat population).
Event No. (%) of Patients
Injection site pain 73 (12.3)
Insomnia 51 (8.6)
Anxiety 40 (6.7)
Psychotic disorder 36 (6.1)
Headache 33 (5.6)
1383
Clinical Therapeuticslonger than achievable otherwise, and it may provide
more meaningful longer-term data over the duration
of the study. Patients in this study were nonacute but
symptomatic and considered as stable by their treating
physician for at least 1 month before enrollment, and
the majority showed a further clinically relevant
improvement of their clinical symptoms. Even more,
approximately one third of patients (30.4%) achieved
a Z50% improvement in PANSS total score regard-
less of their reason for switching. Thus, a considerable
proportion of those patients achieved an improvement
of comparable magnitude to acutely ill patients pre-
viously treated with oral antipsychotic agents in a
6-month study (PALMFlexS; Schreiner/Hargarter
et al: acute patients switched from oral antipsychotics
[manuscript in preparation]). This result is of partic-
ular clinical relevance because it demonstrates that
switching patients who are considered clinically stable
still offers the opportunity to experience some further
improvement in a clinically relevant symptom (includ-
ing negative symptoms). This improvement also ap-
plies to patients switched for reasons other than lack
of efﬁcacy with the previous oral antipsychotic agent.
Psychotic symptoms showed signiﬁcant improvement
from day 8 onward for patients switching for lack of
efﬁcacy and for those switching for other reasons.
These data reﬂect observations in acute patients
switched from oral antipsychotic agents in PALM-
FlexS (Hargarter/Schreiner et al: acute patients
switched from oral antipsychotics [manuscript in
preparation]) and the early treatment response seen
in other studies with PP.52,53
Patient satisfaction with antipsychotic treatment is
an important aspect in improving treatment continu-
ation, as indicated in the SOHO (Schizophrenia Out-
patient Health Outcomes)54 and the CATIE (Clinical
Antipsychotic Trial of Intervention Effectiveness)
studies.23 In the present study, patient satisfaction
and completion rates were high, which support
previous data that positive experiences with LAT
can be associated with high patient acceptance and
even preference.55–57 Patient functioning and illness-
related disabilities in activity and participation im-
proved signiﬁcantly during the study. With only 30%
to 35% of patients with schizophrenia currently
achieving remission58,59 and 13.5% achieving recov-
ery,60 the improved functioning observed here in
schizophrenia patients deemed stable suggests that
further clinically relevant improvement of functioning1384and daily abilities is an important yet achievable
outcome.
In the literature, data suggest that an improvement
in a patient’s subjective well-being is more predictive
of enduring symptomatic remission to antipsychotic
medication than psychotic symptoms in PANSS.61,62
Research indicates that subjective well-being or qual-
ity of life is improved more by atypical antipsychotic
agents than by conventional antipsychotic agents, they
can also inﬂuence treatment adherence, and atypical
agents improve the likelihood of patients achieving
remission.63,64 Collectively, these data strongly sug-
gest that assessing a patient’s perspective of antipsy-
chotic treatment can exert clinical advantages because
this perspective may be associated with increased
adherence and thus improvements in long-term prog-
nosis and outcomes.
AEs are a frequent reason why patients discontinue
their antipsychotic medication.23,65 In the present
study, clinically relevant AEs such as EPMS, sedation,
potentially prolactin-related TEAEs, and weight gain
were low and consistent with randomized controlled
studies with PP.38,39 This ﬁnding suggests that PP is
also generally well tolerated in a more diverse patient
population with higher rates of comorbidities, come-
dications, and substance abuse. Notably, the percent-
age of patients with substance abuse in this study was
lower than expected in routine clinical practice, which
may reﬂect an investigator selection bias. However,
the prevalence of current substance use in patients
with schizophrenia, based on the CATIE study (which
used the Structured Clinical Interview for DSM-IV
Axis I Disorders) was 15.8%,66 a rate which is similar
to that reported in the present study, bearing in mind
it did not use a structured interview for evaluating
substance use disorder. Nevertheless, including pat-
ients with substance use disorder in clinical studies
provides additional useful information for day-to-day
practice.
The mean baseline BMI in this study (27.6 kg/m2)
was comparable to that reported in other large
pragmatic studies, such as the SOHO study67 and in
a cohort of patients with chronic schizophrenia in
Italy.68 It was somewhat lower than that in a recent
US trial33,37 but considerably higher than that re-
ported in the European First-Episode Schizophrenia
Trial.69 These varying ﬁndings highlight that there are
substantial differences between newly diagnosed and
patients with schizophrenia treated longer term, asVolume 36 Number 10
A. Schreiner et al.well as regional differences, that may inﬂuence
antipsychotic choice or dosing. One additional,
clinically interesting observation in the present study
was the decline in the proportion of patients requiring
concomitant use of a benzodiazepine or anticholi-
nergic medication, suggesting that PP can be used
effectively in monotherapy in a higher proportion of
patients compared with previous oral antipsychotic
treatment.
Study limitations include the unblinded treatment
and the lack of an active comparator group. As such,
these data do not provide a head-to-head comparison
between treatments but suggest that suboptimal treat-
ment with 1 antipsychotic medication does not predict
failure with other antipsychotic agents, including PP.
Because this study was unblinded and did not include
a comparison group, reporting bias in the study results
cannot be ruled out. Comparison between treatments
was not the primary aim of this trial, which was
designed to capture data in a setting mimicking daily
clinical practice that is not normally achieved in
randomized controlled trials. Nevertheless, the me-
thod used in this study is consistent with current
standards used in clinical trials and therefore allows at
least some indirect comparisons with data from
interventional studies of a similar design. In addition,
the present study did not exclude patients with current
substance use or abuse, the exception being intra-
venous drug use; this is in contrast to the pivotal
randomized controlled studies in PP that excluded
patients if they had a DSM-IV diagnosis of active
substance dependence within 3 months before screen-
ing.37–39 There was little alcohol/substance use in this
group of patients, and it cannot be ruled out that the
psychiatrists selected patients who they felt would be
most likely to complete the study.
CONCLUSIONS
These data illustrate that nonacute patients with
schizophrenia considered stable by their physician
show further clinically relevant symptom improve-
ment and improvements in measures of functioning
when switched from oral antipsychotic agents
to PP.36
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Supplemental Table. Secondary outcomes, Positive and Negative Syndrome Scale Marder factor scores.
Values are given as mean (SD).
Baseline
Score
LOCF End
Point
Change From Baseline
to LOCF End Point
Positive symptoms factor score (SD)
All patients (n ¼ 589) 19.4 (5.6) 16.0 (6.0) –3.3 (5.4)*
Patients switched for lack of efﬁcacy (n ¼ 143) 21.6 (4.8) 18.5 (6.1) –3.1 (5.6)*
Patients switched for other reasons (n ¼ 446) 18.7 (5.7) 15.3 (5.7) –3.4 (5.4)*
Negative symptoms factor score
All patients (n ¼ 589) 19.6 (5.6) 16.1 (5.7) –3.5 (5.3)*
Patients switched for lack of efﬁcacy (n ¼ 143) 22.4 (5.2) 18.6 (5.3) –3.8 (4.9)*
Patients switched for other reasons (n ¼ 446) 18.6 (5.4) 15.2 (5.6) –3.4 (5.4)*
Disorganized thoughts factor score
All patients (n ¼ 589) 16.2 (4.4) 13.9 (4.6) –2.3 (3.9)*
Patients switched for lack of efﬁcacy (n ¼ 143) 18.3 (3.7) 16.1 (4.1) –2.2 (3.8)*
Patients switched for other reasons (n ¼ 446) 15.5 (4.4) 13.2 (4.5) –2.3 (4.0)*
Uncontrolled hostility/excitement factor score
All patients (n ¼ 589) 7.1 (2.6) 6.2 (2.7) –0.9 (2.9)*
Patients switched for lack of efﬁcacy (n ¼ 143) 7.7 (2.5) 6.7 (2.8) –1.0 (3.1)*
Patients switched for other reasons (n ¼ 446) 6.9 (2.7) 6.0 (2.7) –0.9 (2.8)*
Anxiety/depression factor score
All patients (n ¼ 589) 9.3 (3.1) 7.6 (3.1) –1.7 (3.2)*
Patients switched for lack of efﬁcacy (n ¼ 143) 10.3 (3.2) 8.3 (3.5) –2.0 (3.2)*
Patients switched for other reasons (n ¼ 446) 9.0 (3.0) 7.3 (3.0) –1.6 (3.2)*
LOCF ¼ last-observation-carried-forward.
*P o 0.0001, Wilcoxon signed-rank test.
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